These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 30370041)

  • 1. Efficacy of adalimumab in moderate to severe hidradenitis suppurativa: Real life data.
    Kyriakou A; Trigoni A; Galanis N; Sotiriadis D; Patsatsi A
    Dermatol Reports; 2018 Oct; 10(2):7859. PubMed ID: 30370041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two Cases of Hidradenitis Suppurativa Treated with Adalimumab at the Department of Dermatology and Venereology, Clinical Hospital Mostar.
    Lovrić I; Brkić J; Ćorluka M; Čović M; Pejić J; Zeljko Penavić J
    Acta Dermatovenerol Croat; 2021 Jul; 29(2):108-110. PubMed ID: 34477078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa.
    Gulliver W; Zouboulis CC; Prens E; Jemec GB; Tzellos T
    Rev Endocr Metab Disord; 2016 Sep; 17(3):343-351. PubMed ID: 26831295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical response rate and flares of hidradenitis suppurativa in the treatment with adalimumab.
    Caposiena Caro RD; Cannizzaro MV; Tartaglia C; Bianchi L
    Clin Exp Dermatol; 2020 Jun; 45(4):438-444. PubMed ID: 31630436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adalimumab Treatment in Women With Moderate-to-Severe Hidradenitis Suppurativa from the Placebo-Controlled Portion of a Phase 2, Randomized, Double-Blind Study.
    Gottlieb A; Menter A; Armstrong A; Ocampo C; Gu Y; Teixeira HD
    J Drugs Dermatol; 2016 Oct; 15(10):1192-1196. PubMed ID: 27741335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study.
    Zouboulis CC; Okun MM; Prens EP; Gniadecki R; Foley PA; Lynde C; Weisman J; Gu Y; Williams DA; Jemec GBE
    J Am Acad Dermatol; 2019 Jan; 80(1):60-69.e2. PubMed ID: 29860040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world safety and effectiveness of adalimumab in patients with hidradenitis suppurativa: 12-week interim analysis of post-marketing surveillance in Japan.
    Hayashi N; Hayama K; Takahashi K; Kurokawa I; Okazaki M; Kashiwagi T; Iwashita E; Terui T
    J Dermatol; 2022 Apr; 49(4):411-421. PubMed ID: 35040156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial.
    Kimball AB; Kerdel F; Adams D; Mrowietz U; Gelfand JM; Gniadecki R; Prens EP; Schlessinger J; Zouboulis CC; van der Zee HH; Rosenfeld M; Mulani P; Gu Y; Paulson S; Okun M; Jemec GB
    Ann Intern Med; 2012 Dec; 157(12):846-55. PubMed ID: 23247938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adalimumab Dose Intensification in Recalcitrant Hidradenitis Suppurativa/Acne Inversa.
    Zouboulis CC; Hansen H; Caposiena Caro RD; Damiani G; Delorme I; Pascual JC; Reguiai Z; Trigoni A; Vilarrasa E; Alfageme Roldán F
    Dermatology; 2020; 236(1):25-30. PubMed ID: 31630144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Twenty-four-week interim analysis from a phase 3 open-label trial of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa.
    Morita A; Takahashi H; Ozawa K; Imafuku S; Nakama T; Takahashi K; Matsuyama T; Okubo Y; Kitamura S; Matsuda N; Zhao Y; Yokoyama M; Hayashi N; Terui T
    J Dermatol; 2019 Sep; 46(9):745-751. PubMed ID: 31282051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Effectiveness of Guselkumab in Patients With Hidradenitis Suppurativa Under Clinical Practice Conditions: A Spanish Multicentre Retrospective Study.
    Rivera-Díaz R; Pozo T; Alfageme F; Díaz Ley B; Osorio GF; Chico R; Vilarrasa E; Silvente C; Ciudad Blanco C; Romaní J; Martorell A; Fernández P; Romero Ferreiro C; Molina Leyva A
    Actas Dermosifiliogr; 2023 Oct; 114(9):755-762. PubMed ID: 37331620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effectiveness of Guselkumab in Patients With Hidradenitis Suppurativa Under Clinical Practice Conditions: A Spanish Multicentre Retrospective Study.
    Rivera-Díaz R; Pozo T; Alfageme F; Díaz Ley B; Osorio GF; Chico R; Vilarrasa E; Silvente C; Ciudad Blanco C; Romaní J; Martorell A; Fernández P; Romero Ferreiro C; Molina Leyva A
    Actas Dermosifiliogr; 2023 Oct; 114(9):T755-T762. PubMed ID: 37479135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Certolizumab pegol in the treatment of severe hidradenitis suppurativa after adalimumab failure: A real-life experience.
    Esme P; Akoglu G; Dalkıran CD; Caliskan E
    Dermatol Ther; 2022 Nov; 35(11):e15782. PubMed ID: 35996992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for a 'window of opportunity' in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicentre cohort study.
    Marzano AV; Genovese G; Casazza G; Moltrasio C; Dapavo P; Micali G; Sirna R; Gisondi P; Patrizi A; Dini V; Bianchini D; Bianchi L; Fania L; Prignano F; Offidani A; Atzori L; Bettoli V; Cannavò SP; Venturini M; Bongiorno MR; Costanzo A; Fabbrocini G; Peris K
    Br J Dermatol; 2021 Jan; 184(1):133-140. PubMed ID: 32119111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement in Hidradenitis Suppurativa and quality of life in patients treated with adalimumab: Real-world results from the HARMONY Study.
    Hafner A; Ghislain PD; Kovács R; Batchelor R; Katoulis AC; Kirby B; Banayan H; Schonbrun M
    J Eur Acad Dermatol Venereol; 2021 Nov; 35(11):2277-2284. PubMed ID: 34320249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spotlight on adalimumab in the treatment of active moderate-to-severe hidradenitis suppurativa.
    Fotiadou C; Vakirlis E; Ioannides D
    Clin Cosmet Investig Dermatol; 2016; 9():367-372. PubMed ID: 27799806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-World Moderate-to-Severe Hidradenitis Suppurativa: Decrease in Disease Burden With Adalimumab.
    Gulliver W; Alavi A; Wiseman MC; Gooderham MJ; Rao J; Shayesteh Alam M; Papp KA; Desjardins O; Jean C
    J Cutan Med Surg; 2022; 26(4):361-370. PubMed ID: 35322692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world effectiveness of adalimumab in patients with moderate-to-severe hidradenitis suppurativa: the 1-year SOLACE study.
    Gulliver W; Alavi A; Wiseman MC; Gooderham MJ; Rao J; Alam MS; Papp KA; Desjardins O; Jean C
    J Eur Acad Dermatol Venereol; 2021 Dec; 35(12):2431-2439. PubMed ID: 34378812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apremilast for the Treatment of Mild-to-Moderate Hidradenitis Suppurativa in a Prospective, Open-Label, Phase 2 Study.
    Kerdel FR; Azevedo FA; Kerdel Don C; Don FA; Fabbrocini G; Kerdel FA
    J Drugs Dermatol; 2019 Feb; 18(2):170-176. PubMed ID: 30811140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment.
    Kimball AB; Jemec GB; Yang M; Kageleiry A; Signorovitch JE; Okun MM; Gu Y; Wang K; Mulani P; Sundaram M
    Br J Dermatol; 2014 Dec; 171(6):1434-42. PubMed ID: 25040429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.